Zydus Cadila has received the final approval from the US FDA to market topiramate tablets in different strengths of 25mg, 50mg, 100mg and 200mg. The drug falls in the anti-epileptic segment.
The sale of topiramate tablets as per NDC Health was estimated at USD 2.6 billion in 2008.
The group now has 42 approvals and has s far filed 83 ANDAs since the commencement of filing process in FY 2003-04